Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

34
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
34
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

46
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

906
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
906
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

22
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
22

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Transcatheter aortic valve implantation outcomes by patient age and sex in COMPARE-TAVI 1: a cohort study.

BMJ open·2026
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Making Statistics Clinically Meaningful.

Clinical epidemiology·2026
Same author

Cohort Profile: The Central Denmark Cancer Cohort.

Clinical epidemiology·2026
Same author

Outcomes after inhospital, subacute, and elective TAVI in COMPARE-TAVI 1.

European heart journal open·2026
Same author

Cardiovascular magnetic resonance reclassification of aortic regurgitation after transcatheter aortic valve implantation: A COMPARE-TAVI 1 substudy.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026

関連する実験動画

Updated: Aug 14, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

低密度の脂質タンパク質のコレステロールは,冠動脈硬化症の証拠を有する患者の動脈硬化性心血管疾患の発生と主として関連している:西デンマーク心臓登録局

Martin Bødtker Mortensen1,2, Omar Dzaye2, Hans Erik Bøtker1

  • 1Departments of Cardiology (M.B.M., H.E.B., J.M.J., M.M., J.F.B., H.K., B.L.N.), Aarhus University Hospital, Denmark.

Circulation
|January 9, 2023
PubMed
まとめ

低密度の脂質タンパク質コレステロール (LDL-C) は,冠動脈化 (CAC) の個体においてのみ,動脈硬化性心血管疾患 (ASCVD) の発生と関連しています. CACの存在は,中年の成人の将来のASCVDリスクを予測するために,LDL-Cに不可欠です.

キーワード:
動脈カルシウム心血管疾患コホート研究コンピュータトモグラフィー 血管図冠動脈疾患冠動脈血管流行病学について脂質タンパク質,LDLリスク

さらに関連する動画

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

関連する実験動画

Last Updated: Aug 14, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

科学分野:

  • 心臓病科
  • 予防医学
  • 医療用イメージング

背景:

  • 低密度の脂質タンパク質コレステロール (LDL-C) は,動脈硬化性心血管疾患 (ASCVD) の因果的な危険因子として知られています.
  • 冠動脈硬化 (CAC) によって示されるように,高いLDL-Cを持つ中年個人の有意な数は冠動脈硬化を示さない.
  • LDL-CとASCVDのリスクとの関連性に対するCACの存在の影響は不明である.

研究 の 目的:

  • CACの存在がLDL-Cレベルと将来のASCVDのリスクとの関連性を変化させるかどうかを調査する.
  • 冠動脈動脈硬化症の証拠のある患者およびない患者のASCVDに対するLDL- Cの予測値の評価.

主な方法:

  • 冠動脈計算機断層検査 (CTA) を受けた23132人の症状のある患者の分析.
  • ベースラインのLDL- C値とASCVDイベント (心筋梗塞,不全性脳卒中) の関連性を考察する.
  • 冠動脈結晶の存在 (CAC>0) または欠如 (CAC=0) による分析の分層化で,結果は多民族性動脈硬化研究 (MESA) で再現された.

主要な成果:

  • 全体的なコホートでは,LDL- Cの上昇はASCVDのリスクの増加と関連していました (aHR,1. 14).
  • この関連性は,CAC> 0 (aHR,1.18) の患者では有意であったが,CAC=0 (aHR,1. 02) の患者では有意ではなかった.
  • 非常に高いLDL- C (>193 mg/ dL) は,CAC>0 (aHR,2. 42) の患者ではASCVDのリスクを有意に増加させたが,CACのない患者ではそうではなかった (aHR,0. 92).

結論:

  • 約5年間のLDL-CとASCVDの関連性は,主として冠動脈硬化症 (CAC>0) の証拠を有する中年個体において観察された.
  • 主に冠動脈動脈硬化がある場合,LDL-CはASCVDリスクの有意な予測因子であるようです.
  • 発見は,中年の集団における個別化されたASCVDリスク評価のために,CACとLDL-Cを併用して使用することを支持しています.